Hahn, Deanna
Hahn, Deanna was paid $182K by Medicaid between Jan 2018 and Apr 2024, across 17 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 39% of everything it billed.
33Billing provider infoHAHN, DEANNA
BLOOMINGTON, IL 61701
BLOOMINGTON, IL 61701
33aNPI1629026398assigned 05/05/2006
33bProvider typeSpecialist
28Total paid$182K
24GClaims3,503
24DCodes billed17
24AFirst – last monthJan 2018 – Apr 2024
Compared with peers
Next to other Specialist providers in Illinois
Rank by total paid#58 of 273
Median peer was paid$32K
This provider vs. median5.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 252 | $11K | |
| 2019 | 370 | $17K | |
| 2020 | 429 | $16K | |
| 2021 | 1,078 | $52K | |
| 2022 | 605 | $33K | |
| 2023 | 565 | $37K | |
| 2024incomplete | 204 | $15K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 39% | 1,495 | 1,241 | $71K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 32% | 772 | 682 | $58K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 12% | 292 | 168 | $22K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 3.7% | 95 | 75 | $7K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.5% | 46 | 42 | $6K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2.7% | 63 | 51 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.5% | 88 | 82 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 46 | 44 | $2K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.0% | 104 | 91 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.0% | 75 | 68 | $2K |
| 96127 | <1% | 108 | 88 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 13 | 13 | $934.18 |
5 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.